Allied Market Research


Relapsing-remitting Multiple Sclerosis Market

Relapsing-Remitting Multiple Sclerosis Market Size, Share, Competitive Landscape and Trend Analysis Report by Treatment, by Route of Administration and by End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Therapeutics

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Relapsing-remitting multiple sclerosis (RRMS) is a kind of multiple sclerosis. It is the most common type of multiple sclerosis (MS), accounting for around 85% of source of diagnoses. Relapses of MS occur in people with RRMS with periods of remission occurring in between. MS is a chronic, progressive condition of the central nervous system (CNS) in which your immune system attacks myelin, the protective layer around nerve fibers. Damage of the myelin causes the nerves inflammation, which makes it difficult for your brain to connect with the rest of your body.

The specific causes of RRMS and other types of MS is currently unknown. A combination of genetic and environmental factors, such as smoking, vitamin D deficiency, and certain viral infections, may all play a role. Although there is no cure for MS,  but treatment can help manage symptoms, treat relapses, and slow down the progression of the condition. A variety of medications and therapies are available. For example, medications can help with symptoms like fatigue and muscle stiffness. A physiotherapist can assist with mobility difficulties or muscle weakness.

COVID-19 Impact Analysis

COVID-19 is an infectious disease that first emerged in late December in the Hubei province of the Wuhan city in China. The virus that causes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),  is highly infectious and, is transmitted from person to person. Since the outbreak in December 2019, The disease has spread to almost 213 countries across the globe with the World Health Organization to declare it a pandemic on March 11, 2020.

Coronavirus disease 2019 (COVID-19) has caused an economic crisis along with the healthcare crisis. The COVID-19 pandemic has stretched the global healthcare system, and  developed countries are anticipated to experience an economic recession as a result. The pandemic has had an adverse impact on the healthcare system, with revenue dropping by a 50% to 70% drop since March. Several small hospitals, clinics, and nursing homes have been forced to shut their operations Furthermore, social distancing and localized curfews have resulted in delayed elective surgical procedures. Moreover, visa cancellations have disrupted medical tourism which can negatively impact the growth of relapsing-remitting multiple sclerosis market.

During the spread of the pandemic, however, the testing scale has increased, allowing for data sharing and provides reliable lab results.

Top Impacting Factors

An increase in the geriatric population is driving the growth of the global relapsing-remitting multiple sclerosis market. According to a recent study, one in every six people in the world would be 65 and older by the end of 2050. The situation is more pronounced in Europe and North America where  one in every four people will be affected. Already in 2018 the population of this age group has surpassed that of children aged 5 and under. This Increase in geriatric population will need healthcare facilities, which is expected to enhance growth of the  relapsing-remitting multiple sclerosis market.

The cost of drugs remains a major challenge for the growth of the market due to increased government interventions and various treatment options for multiple sclerosis. However, patent expiry of major drugs is key restraint of the global MS drugs market. Furthermore, stringent regulatory constraints restrict the growth of the global MS drugs market.

Key Market Trends

Monoclonal antibodies are now being increasingly employed for the treatment of RRMS. Many clinical trials are focused on novel drugs using antibodies. There is an increase in the demand for immunosuppressive drugs for treating this condition..

F. Hoffman-La Roche Ltd., launched Ocrevus in 2017, and it soon became one of the blockbusters profits -making drug.

Key Benefits of the Report

  • This study presents the analytical depiction of the relapsing-remitting multiple sclerosis market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the relapsing-remitting multiple sclerosis market share.
  • The current market is quantitatively analyzed to highlight the growth scenario of the relapsing-remitting multiple sclerosis market..
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and the competition that will take shape in the coming years.

Questions Answered in the Adenovirus Diagnostic Testing Report

  • Who are the leading market players active in the relapsing-remitting multiple sclerosis market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the relapsing-remitting multiple sclerosis market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What are the future projections that would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is relapsing-remitting multiple sclerosis?
  • What is the prediction of the relapsing-remitting multiple sclerosis market in the future?
  • What are the current and predicted trends?

Relapsing-Remitting Multiple Sclerosis Market Report Highlights

Aspects Details
By Treatment
  • Immunomodulating Drugs
  • NrF2 Activators
  • Interferons
  • Others
By Route of Administration
  • Oral
  • Intravenous
By End User
  • Hospitals
  • Clinics
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players

Roche, GlaxoSmithKline, Novartis, Pfizer, Inc., Biogen, Bayer HealthCare, Sanofi, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Merck and Co., Inc.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Relapsing-Remitting Multiple Sclerosis Market

Global Opportunity Analysis and Industry Forecast, 2023-2032